Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC
Replace the toughest part of pre-surgery chemotherapy with an ADC plus immunotherapy, aiming for the same cure rate with less harm.
KEYNOTE-522's backbone includes anthracyclines with cardiac and leukaemia risk. ADCs + pembrolizumab achieve high response rates in metastatic disease; NeoSTAR (sacituzumab) and I-SPY 2 arms show meaningful pCR rates.
Pages like this
not linked directly; found by shared links- TrialTROPION-Breast05
Shares ADC + checkpoint inhibitor, Datopotamab deruxtecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- IdeaADC for residual disease after KEYNOTE-522
Shares KEYNOTE-522, Sacituzumab govitecan, Datopotamab deruxtecan, Pembrolizumab.
- TrialASCENT-04 / KEYNOTE-D19
Shares ADC + checkpoint inhibitor, Sacituzumab govitecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- PersonPriyanka Sharma
Shares SCARLET (SWOG S2212), Pembrolizumab, Triple-negative breast cancer (TNBC).
- TrialASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)
Shares KEYNOTE-522, Sacituzumab govitecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast03
Shares KEYNOTE-522, Datopotamab deruxtecan, Pembrolizumab, Triple-negative breast cancer (TNBC).
- PairingTROP2 PET → TROP2 ADC selection
Shares Sacituzumab govitecan, Datopotamab deruxtecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Sacituzumab govitecan, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC).